Will one of the GLP agonist drugs (eg Semaglutude/Wegovy Tirzepatide/Mounjaro) have a black box warning by 2025
Standard
21
Ṁ9232026
33%
chance
1D
1W
1M
ALL
a black box warning by FDA or withdrawal from market for adverse events by 12/31/2025 resolves this market YES
Get
1,000
and1.00
Sort by:
made a related market and added a large subsidy: https://manifold.markets/AndyMartin/m5k-subsidy-will-any-fdaapproved-gl?r=QW5keU1hcnRpbg
More reports of gastroparesis https://www.cnn.com/2023/07/25/health/weight-loss-diabetes-drugs-gastroparesis/index.html
Related questions
Related questions
[M$5k subsidy] Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by...
Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?
30% chance
The FDA will warn about overuse or misuse of semaglutide (Ozempic, Wegovy and Rybelsus) before the end of 2024.
23% chance
Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027
75% chance
Will 10 million Americans be on semaglutide (or yet-to-be-approved equally good or superior alternatives) by the end of 2030?
78% chance
Will Ozempic / semaglutide be FDA-approved for Alzheimer's before 2030?
64% chance
Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by 01/01/2025?
14% chance
What fraction of US adults will regularly take GLP-1 drugs in 2030?
Will there be a recall of Wegovy/Ozempic before 2035?
62% chance
Will a drug company pay >$1m in a class action suit based on their statements about their GLP1 inhibitor by 2026?
38% chance